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ABSTRACT
Within populations carrying the same genetic predisposition, the penetrance 
of BRCA1 mutations has increased over time. Although linked to changes in lifestyle 
factors associated with energy metabolism, these observations cannot be explained 
by the established role of BRCA1 in DNA repair alone. 
We manipulated BRCA1 expression using tetracycline in the UBR60-bcl2 cell 
line (which has an inducible, tetracycline-regulated BRCA1 expression) and siRNA in 
oestrogen receptor(ER)-positive MCF7 and T47D breast cancer cells. Cellular responses 
to BRCA1 silencing and IGF-I actions were investigated using western blotting, 3-H 
Thymidine incorporation assay, cell fractionation and co-immunoprecipitation. 
We demonstrated that the loss of BRCA1 resulted in downregulation of a 
phosphorylated and inactive form of acetyl CoA Carboxylase-α (ACCA), with 
a concomitant increase in fatty acid synthase (FASN) abundance. BRCA1 was 
predominantly cytoplasmic in ER-positive breast cancer cells, compatible with the 
observation that BRCA1 physically associates with phosphorylated ACCA, which is a 
cytoplasmic protein. We also found that IGF-I induced de-phosphorylation of ACCA by 
reducing the interaction between BRCA1 and phosphorylated ACCA. BRCA1 deficiency 
enhanced the non-genomic effects of IGF-I, as well as the proliferative responses of 
cells to IGF-I. 
We characterized a novel, non-genomic role for BRCA1 in restraining metabolic 
activity and IGF-I anabolic actions.
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INTRODUCTION
The breast cancer 1, early onset (BRCA1) gene is 
frequently mutated in familial breast cancers and women 
harbouring these germline mutations have an increased 
risk of developing breast cancer [1, 2]. Although somatic 
mutations are rare in sporadic breast cancers, BRCA1 
dysfunction has also been reported in a large number of 
these cases [3–5]. The BRCA1 gene product has established 
roles in the maintainance of genome integrity [6–8], 
however, the increasing penetrance of BRCA1 mutations 
over time within populations carrying the same genetic 
predisposition [2, 9] suggests that BRCA1 may be involved 
in other roles beyond the genome. Indeed, BRCA1 has 
recently been shown to play a regulatory role in lipogenesis 
by interacting with Acetyl CoA carboxylase-α (ACCA) in a 
phospho-dependent manner [10–12].
Acetyl CoA carboxylase exists as ACCA and 
acetyl CoA carboxylase-ß (ACCB) isoforms, with 
ACCA involved in de novo fatty acid synthesis in the 
cytosol whereas ACCB regulates mitochondrial fatty acid 
oxidation on the outer mitochondrial membrane [13]. 
In the fatty acid synthesis pathway, ACCA catalyses the 
rate-limiting step of the pathway and generates substrates 
for fatty acid synthase (FASN) [14]. Phosphorylation of 
a number of serine residues has been shown to regulate 
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ACCA by reducing its activity [15, 16] and among 
these, Ser-79 has been identified as a major regulatory 
site [17]. The formation of a complex between BRCA1 
and p-ACCA (S79) prevents dephosphorylation of ACCA 
[10], thus acting as a brake on tumour cell anabolism 
and proliferation. Disruption of this complex due to 
BRCA1 protein dysfunction resulting from either BRCA1 
gene mutation or epigenetic silencing, may have huge 
implications for tumour cell anabolism.
Insulin-like growth factor-I (IGF-I) is a peptide 
hormone that plays an important role in normal mammary 
growth and development and its effects are mainly 
mediated through the type 1 IGF receptor (IGF-IR) [18]. 
In many epithelial tumours, including those of the breast, 
high circulating levels of IGF-I have been correlated 
with increased cancer risk and the IGF-IR is frequently 
overexpressed in the tumours [19, 20]. These observations 
suggest that IGF-I and its receptor play a key role in 
carcinogenesis. Additionally, the IGF-I/IGF-IR signalling 
pathway negatively correlates with BRCA1 abundance 
in breast and prostate cancer cells [21, 22], suggesting an 
interplay between BRCA1 and IGF-I/IGF-IR signalling. 
We recently made a novel observation that IGF-I regulates 
FASN abundance in non-malignant mammary epithelial 
cells and estrogen receptor (ER)-positive breast cancer 
cells [23]. However, the proliferative response to IGF-I was 
only dependent upon FASN in ER-positive breast cancer 
cells and not in non-malignant breast epithelial cells. 
These data provided a link between an established role of 
IGF-I as a cell cycle regulator with a role in lipogenesis. 
Although BRCA1 may also regulate cell cycle through its 
role in lipogenesis [15], little is known about the extent of 
BRCA1 involvement in the fatty acid synthesis pathway 
and how BRCA1 deficiency may impact on IGF-I actions. 
In this study, we report that BRCA1 is predominantly 
localised to the cytoplasm in ER+ breast cancer cells where 
it associates with p-ACCA (S79). In cells expressing full-
length, wildtype BRCA1, IGF-I induces dephosphorylation 
of ACCA by reducing the interaction between BRCA1 
and p-ACCA (S79), with a concomitant increase in FASN 
abundance downstream of ACCA. BRCA1 deficiency also 
results in a reduction in the inactive form of ACCA and 
subsequently, an increase in FASN. Additionally, BRCA1 
deficiency enhances the non-genomic effects of IGF-I and 
the proliferative responses of cells to IGF-I. With the data 
presented here, we characterized a novel, non-genomic 
role for BRCA1 in breast tumour suppression, contributing 
to a growing list of emerging BRCA1 functions.
RESULTS
BRCA1 negatively regulates ACCA and FASN in 
UBR60-bcl2 and ER-positive breast cancer cells
Recent evidence showed that BRCA1 regulates 
lipogenesis through its interaction with the phosphorylated 
and inactive form of the ACCA enzyme [11, 24]. This 
interaction acts as a brake on lipogenesis by preventing 
dephosphorylation of ACCA, keeping it in this inactive 
state. We reasoned that BRCA1 abundance affects key 
enzymes of the fatty acid synthesis pathway. Using 
UBR60-bcl2 cell line with an inducible, tetracycline-
regulated BRCA1 expression described previously [25], 
we show that BRCA1 induction resulted in an increase 
in ACCA phosphorylation (Figure 1A). In addition to 
increasing ACCA phosphorylation, the induction of 
BRCA1 also caused a significant reduction in FASN 
abundance (Figure 1B). These data suggest that BRCA1 
favours the maintenance of ACCA in an inactive state and 
low FASN abudance downstream. To investigate whether 
the effects could be replicated in breast cancer cells, we 
used short interfering RNA (siRNA) to downregulate 
endogenous BRCA1 in ER-positive MCF7 and T47D 
breast cancer cell lines which have relatively high 
abundance of BRCA1 (Supplementary Figure 1). BRCA1 
siRNA 1 and siRNA 2 targeting different sequences of 
the BRCA1 gene, reduced ACCA phosphorylation and 
increased FASN abundance in both MCF7 (Figure 
2A–2C) and T47D (Figure 2D–2F) breast cancer cells. 
BRCA1 is predominantly cytoplasmic in ER-
positive breast cancer cell lines and physically 
interacts with phosphorylated ACCA
The data showing that BRCA1 physically binds 
ACCA, which is a cytoplasmic protein [10–12], suggest that 
BRCA1 has metabolic roles that requires it to be localised to 
the cytoplasm. However, there has been conflicting reports 
regarding the subcellular localisation of the BRCA1 protein 
in breast cancer cells [4, 26]. To study the sub-cellular 
localisation of BRCA1, we selected two ER-positive breast 
cancer cell line models (MCF7 and T47D), two ER-negative 
breast cancer cell lines (MDA-MB-231 and Hs578T) and a 
normal breast cell line (MCF10A) for analysis. We found 
that BRCA1 was predominantly localised in the nuclei of 
the ER-negative MDA MB 231 and Hs578T cells using 
subcellular fractionation method (Figure 3A and 3B). 
In contrast, BRCA1 was predominantly localised in the 
cytoplasm of MCF7 and T47D breast cancer cells which 
are ER-positive (Figure 3C and 3D). This localisation 
pattern was confirmed using immunofluorescence 
(Figure 3E). In a normal mammary epithelial cell line 
MCF10A however, BRCA1 was predominantly nuclear 
(Figure 3F and 3G). To demonstrate the relevance of 
cytoplasmic BRCA1 in cell metabolism, we confirmed 
the association between endogenous BRCA1 and 
phosphorylated ACCA in MCF7 and T47D breast cancer 
cells using co-immunoprecipitation. As expected, p-ACCA 
(S79) co-precipitated with BRCA1 and reciprocally, BRCA1 
co-precipitated with p-ACCA (S79) in both MCF7 and T47D 
breast cancer cells (Supplementary Figure 2A and 2B). 
Control IgG did not yield any interactions. 
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IGF-I induces dephosphorylation of ACCA and 
increases FASN abundance in ER-positive breast 
cancer cell lines
Next, we investigated how IGF-I may regulate key 
enzymes of the fatty acid synthesis pathway. ACCA, which 
catalyses a rate-limiting step of the fatty acid synthesis 
pathway, is activated by dephosphorylation on serine-79 
residues and produces substrates for FASN [15, 16, 27]. 
In both MCF7 and T47D cells, our data show that IGF-I 
induces dephosphorylation of ACCA and upregulates 
FASN downstream of ACCA (Figure 4A and 4B). These 
data suggest that IGF-I favours fatty acid synthesis by 
promoting the active state of ACCA and increasing FASN 
abundance. 
IGF-I induces dephosphorylation of ACCA by 
reducing the interaction between BRCA1 and 
p-ACCA (S79)
Our aforementioned data show that IGF-I 
dephosphorylates ACCA in luminal breast cancer cell lines 
which are known to express full-length, wildtype BRCA1 
[28, 29]. Since BRCA1 regulates fatty acid synthesis by 
preventing the dephosphorylation of ACCA [10], these 
data then suggest that IGF-I somehow circumvents the 
protective role of BRCA1. We therefore hypothesised that 
IGF-I induces dephosphorylation of ACCA by reducing the 
interaction between BRCA1 and p-ACCA (S79). To study 
the impact of IGF-I on the association between BRCA1 
and p-ACCA (S79), lysates from MCF7 and T47D cells 
Figure 1: BRCA1 regulates ACCA and FASN in UBR60-bcl2 cells. Cells cultured with or without tetracycline for 48 hours 
were lysed and analyzed by western blotting. (A) Representative immunoblots of BRCA1, p-ACCA (S79) and total ACCA from three 
independent experiments are shown. The graph shows densitometry analysis of total ACCA normalised to α-tubulin and p-ACCA (S79) 
normalised to both α-tubulin and total ACCA. (B) Representative immunoblots of BRCA1, FASN and α-tubulin from three independent 
experiments are shown. The graph shows densitometry analysis of FASN normalized to α-tubulin. All the densitometry data are expressed 
are expressed as mean ± S.E.M of three independent experiments. *P < 0.05, **P < 0.01 and ***p < 0.001, Student’s t-test (tet− versus tet+).
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treated with IGF-I were subjected to immunoprecipitation 
using a BRCA1 antibody and analysed using western 
blotting. Compared with control, IGF-I reduced the 
amount of p-ACCA (S79) co-precipitating with BRCA1 in 
both MCF7 and T47D breast cancer cell lines (Figure 5A 
and 5B). The interaction between BRCA1 and p-ACCA 
(S79) has previously been shown to be dependent on the 
level of ACCA phosphorylation [10]. Since we have 
also shown that IGF-I reduces ACCA phosphorylation, a 
caveat was whether the observed changes were secondary 
to ACCA dephosphorylation. To rule out this possibility, 
we used okadaic acid, a protein phosphatase inhibitor 
to inhibit dephosphorylation of ACCA by IGF-I. As 
expected, the IGF-I-induced dephosphorylation of ACCA 
Figure 2: BRCA1 silencing up-regulates ACCA and FASN in MCF7 and T47D breast cancer cells. Cells were transfected 
with two BRCA1 siRNAs (siRNA1 and siRNA2) targeting different sequences of BRCA1 or with non-silencing siRNA (NS) as negative 
control for 48 hrs. The abundance of BRCA1, p-ACCA (S79), total ACCA and FASN were analyzed using western blotting with GAPDH 
as a loading control. Representative blots are shown for (A) MCF7 and (D) T47D cells. (B, E) The graphs show densitometry analysis of 
total ACCA normalized to GAPDH and p-ACCA (S79) normalized to both GAPDH and total ACCA. (C, F) The graphs show densitometry 
analysis of FASN normalized to GAPDH. All the densitometry data are expressed are expressed as mean ± S.E.M of three independent 
experiments. *P < 0.05, **P < 0.01 and ***p < 0.001, one-way ANOVA.
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Figure 3: BRCA1 is predominantly cytoplasmic in ER-positive breast cancer cells. (A–D) Nuclear (N), cytoplasmic (C) 
and whole cell extracts (T) were prepared from ER-negative breast cancer cells (A) MDA MB-231 and (B) Hs578T, the ER-positive (C) 
MCF7 and (D) T47D breast cancer cells, as well as a (F) normal mammary epithelial cell line MCF10A. Protein extracts were resolved 
by SDS-PAGE gel and immunoblotted with antibodies against BRCA1, Lamin A/C and α-tubulin. Lamin A/C and α-tubulin were used to 
loading controls for the nuclear and cytoplasmic fractions respectively. Representative images of immunofluorescence staining for BRCA1 
localisation in (E) Hs578T, MDA-MB-231, MCF7 and T47D breast cancer cells and (G) normal mammary epithelial cells MCF10A are 
shown. The cells were labelled with anti-BRCA1 (Ab-1) antibody and the signal was detected with green fluorescent Alexa Fluor® 488 
anti–Mouse IgG. The nuclei were counterstained with blue fluorescent 4′,6-diamidino-2-phenylindole (DAPI). Cells were visualised under 
Zeiss Axio Vert A1 inverted microscope (Zeiss) and the images were captured with a QIClick CCD Camera (Q Imaging) and processed 
with Q-capture pro software. Scale bar represents 50 µm.
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was effectively inhibited in the presence of okadaic acid 
(Figure 5C). This inhibition ensured that the level of 
ACCA phosphorylation was similar between cells treated 
with IGF-I and the control. Using this approach, our 
immunoprecipitation data showed that IGF-I reduced the 
association between BRCA1 and p-ACCA (S79) even when 
ACCA dephosphorylation was inhibited (Figure 5D). 
This suggests that the reduction in the association 
between BRCA1 and p-ACCA (S79) is independent of 
the abundance of phosphorylated ACCA, ruling out 
the possibility that the reduction in the association is 
secondary to ACCA dephosphorylation. 
BRCA1 silencing enhances the effects of IGF-I in 
MCF7 breast cancer cells
Several studies have shown that IGF-I and the IGF-
IR are upregulated in the absence of BRCA1 in different 
in vitro and in vivo models [30–32]. We sought to 
investigate whether BRCA1 loss might also enhance 
the effects of IGF-I in our model. Surprisingly, silencing 
BRCA1 only modestly enhanced the phosphorylation 
of the IGF-IR by IGF-I (Supplementary Figure 3A). 
Interestingly, we also observed a moderate reduction in 
the total levels of the IGF-IR in response to IGF-I when 
Figure 4: IGF-I affects fatty acid synthesis by inducing de-phosphorylation of ACCA and increasing FASN abundance 
in ER-positive breast cancer cell lines. Western blot analysis of (A) MCF 7 and (B) T47D cells treated with 0, 10 and 50 ng/ml IGF-I 
for 48 hours. Representative blots of each protein from at least three experiments are shown. The graphs show densitometry analyses of 
p-ACCA (S79) normalized to total ACCA and FASN normalized to α-tubulin. Each bar represents mean ± S.E.M. of three independent 
experiments. *P < 0.05, **P < 0.01 and ***p < 0.001, one-way ANOVA.
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Figure 5: IGF-I reduces the interaction between BRCA1 and p-ACCA (S79) in MCF7 and T47D ER-breast cancer 
cells. (A) T47D and (B) MCF7 cells were stimulated with 25 ng/l of IGF-I for 30 minutes. The lysates were immunoprecipitated with 2 μg 
anti-BRCA1 antibody or negative control IgG, followed by western blotting using BRCA1 and p-ACCA (S79) antibodies. Inputs represent 
lysates not used for immunoprecipitation. P-ACCA (S79) signal intensity was normalized to BRCA1 and presented graphically besides 
the representative blots. Three independent experiments were conducted and the data is presented as mean ± SE. *p < 0.05, **p < 0.01 and 
***p < < 0.001, Student’s t-test (IGF-I versus control). (C, D) MCF7 cells were pre-incubated with (+) or without (−) okadaic acid (1 μM) 
for 30 minutes and spiked with either serum-free media (−) or 25 ng/ml IGF-I (+) for an additional 30 minutes. (C) Representative blots 
of p-ACCA (S79) and total ACCA are shown. (D) Lysates were subjected to immunoprecipitation with either anti-BRCA1 antibody or 
isotype-matched negative control IgG and immunoblotted with BRCA1 and p-ACCA (S79) antibodies. Input represent lysates not used for 
immunoprecipitation. Representative blots from three independent experiments are shown.
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BRCA1 was silenced, which was not observed under non-
silencing conditions. Downstream of the IGF-IR however, 
the activation of AKT phosphorylation by IGF-I was 
higher when BRCA1 was silenced compared to control 
siRNA (Supplementary Figure 3B). Next, we asked 
whether BRCA1 silencing could also enhance ACCA 
dephosphorylation induced by IGF-I. For this, we silenced 
BRCA1 in the MCF7 cell line and treated these cells with 
IGF-I for 30 minutes. In cells transfected with control 
siRNA, IGF-I moderately induced de-phosphorylation of 
ACCA, but this effect was significantly enhanced in the 
cells transfected with BRCA1 siRNA (Figure 6A). 
We also further investigated the role of BRCA1 
in regulating the proliferative response of cells to IGF-I. 
In the UBR60-bcl2 cells with tetracycline-regulated 
BRCA1 expression [25], BRCA1 expression was 
repressed by tetracycline (Tet+, BRCA1 off) and induced 
by tetracycline withdrawal (Tet-, BRCA1 on). The cells 
were then stimulated with increasing doses of IGF-I for 
24 hours. IGF-I induced cell proliferation under both 
conditions, however, the cells with repressed BRCA1 
displayed an increased and sustained response to IGF-I, 
especially at higher doses when compared with cells 
overexpressing BRCA1 (Figure 6B). Next, we sought to 
replicate these observations in a breast cancer cell line. 
For this, MCF7 cells transfected with BRCA1 siRNA 
and control siRNA were incubated with increasing doses 
of IGF-I for 24 hours. Similar to UBR60-bcl2 cell line, 
MCF7 cells with siRNA-mediated BRCA1 repression 
displayed an enhanced response to IGF-I which was 
sustained at all doses of IGF-I in contrast to control siRNA 
(Figure 6C). 
DISCUSSION 
Until recently, all the known cellular functions 
of BRCA1 were linked to the genome [6–8]. In the 
background of higher disease penetrance among BRCA1/2 
mutation carriers in recent cohorts compared to older 
cohorts with the same genetic predisposition, lifestyle 
factors have been associated with a significant impact on 
disease onset [2, 33]. These observations appear to link 
BRCA1 with roles beyond the genome such as in the 
regulation of metabolic status. 
Here we report that BRCA1 plays a key role in 
lipogenesis by regulating ACCA phosphorylation and 
FASN abundance downstream of ACCA. An increase 
in ACCA phosphorylation following BRCA1 induction 
in UBR60-bc2 cells is consistent with the data showing 
that BRCA1 binds the phosphorylated and inactive form 
of ACCA [11, 12], protecting it from dephosphoryation. 
The association between BRCA1 and phosphorylated 
ACCA restrains endogenous fatty acids synthesis [10] 
and this effect is further reflected by a reduction in FASN 
abundance downstream of ACCA in our UBR60 cell 
model. Similarly, siRNA-mediated reduction of BRCA1 
in breast cancer cells resulted in a decrease in ACCA 
phosphorylation and an increase in FASN abundance. 
Since BRCA1 acts as a brake on lipogenesis by binding 
phosphorylated ACCA, the loss of BRCA1 is consistent 
with releasing this brake and allowing synthesis of long 
chain saturated fatty acids. A similar effect has been 
demonstrated in human adipose tissue. In pre-adipocytes, 
increased BRCA1 expression correlated with an increase 
in ACCA phosphorylation and FASN downregulation 
to inhibit fatty acid synthesis [34]. In contrast however, 
BRCA1 expression was reduced during adipogenesis, 
resulting in decreased ACCA phosphorylation and an 
increase in FASN to allow lipogenesis [34]. Cancer 
cells typically exhibit lipogenic phenotype characterised 
by upregulation of lipogenic enzymes and increased 
endogenous synthesis of fatty acids [35]. Our data showing 
that BRCA1 regulates ACCA phosphorylation and FASN 
abundance suggests that the impairment of this function 
by germline mutations or by epigenetic events may 
favour carcinogenesis. It has been shown that decreased 
BRCA1 in skeletal muscle resulted in increased storage 
of intracellular lipid and reduced insulin signalling [36]. 
In addition, an imaging spectroscopy study examining 
metabolite levels in breast tissue of women with BRCA 
mutations but without evidence of cancer, identified 
changes in lipid levels [37]. These studies indicate a 
normal role for BRCA1 in regulating lipid metabolism in 
tissues and specifically in the breast. In light of our data, 
we believe it would be interesting in future work to assess 
additional metabolic changes, such as altered metabolic 
products as a consequence of BRCA1 dysfunction. 
Shortly after BRCA1 was cloned in 1994, early 
research into the BRCA1 gene product suggested it was 
an exclusively nuclear protein with little or no known 
cytoplasmic functions [38]. At the time, the maintenance 
of genome integrity was the most described and widely 
accepted role of BRCA1, therefore the cytoplasmic 
localisation of BRCA1 reported in several studies 
[39, 40] was incompatible with this function. The recently 
discovered functions of BRCA1, such as in fatty acid 
synthesis, clearly dictate that BRCA1 should be localised 
in the cytoplasm to carry out these functions. The 
association between BRCA1 and phosphorylated ACCA 
reported by others [10, 11] and confirmed in our study, 
also suggests that BRCA1 would have to be cytoplasmic 
for this interaction to occur. The cytoplasmic localization 
of BRCA1 was also confirmed in clinical specimens 
in a study of 103 women with breast cancer, where 
cytoplasmic localisation of BRCA1 was found in 51.4% of 
tumours and exclusive nuclear localisation was only found 
in a minority of cases [41].
Our study is the first to demonstrate a clearly 
defined localisation pattern between cell line models of 
ER-positive and ER-negative breast cancer subtypes. 
Although the reason for this novel distribution pattern is 
currently unclear, it is possible that it reflects the intrinsic 
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molecular subtypes of breast tumours. More importantly, 
this localisation pattern suggests that besides technical 
differences, biological heterogeneity may also underlie 
the discrepant data on BRCA1 localisation in unselected 
samples in different studies [3, 4, 39, 42].
Clinically, our data is consistent with the findings 
that cytoplasmic BRCA1 is a feature of less aggressive 
ER-positive breast cancers with good prognosis 
[39, 40]. Interestingly, the ER-positive breast cancer cell 
lines used in this study typically display less aggressive 
phenotypes when compared to ER-negative breast cancer 
cells [43, 44]. However, a more recent study reported no 
prognostic value of BRCA1 localisation, but restriction 
of the analysis to patients aged >40 years revealed an 
association between cytosolic BRCA1 and metastasis 
[45]. In the Santivasi et al. study however, unlike in the 
Figure 6: BRCA1 silencing enhances IGF-I signaling and effects on ACCA. (A, B) MCF7 breast cancer cells were transfected 
with BRCA1 siRNA or control siRNA for 48 hours before stimulation with 25 ng/ml IGF-I for 30 minutes. (A) Representative blots of 
western blotting analysis of p-ACCA (S79) and total ACCA are shown. The graph shows densitometry analyses of p-ACCA (S79) normalized 
to total ACCA. Each bar represents mean ± S.E.M. of three independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001, one-way 
ANOVA. (B) UBR60-bcl2 cells with or without 1 mg/ml tetracycline and (C) MCF7 cells transfected with control siRNA or BRCA1 
siRNA were treated with increasing doses (0–200 ng/ml) of IGF-I for 24 hours. The cells were pulsed with [3H]-labelled thymidine 
(1 μCi) 4 hours before the end of the experiment. The radioactive label was precipitated with trichloracetic acid, solubilised with sodium 
hydroxide and the signal was detected using liquid scintillation counter. The experiments were repeated 3 times and results are expressed 
as percentage increase for treatment over control. The graphs represent mean ± S.E.M. of three independent experiments. 
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other studies, cytoplasmic BRCA1 was reported to be a 
marker of poor prognosis. The reasons for this conflicting 
prognostic value of BRCA1 localisation are unknown and 
warrant further investigation.
ACCA catalyses the rate limiting step of the 
fatty acid synthesis pathway and has been shown to be 
important to the survival of cancer cells [24, 46, 47]. 
Phosphorylation reduces ACCA activity by reducing 
its Vmax and sensitivity to allosteric activation by citrate 
[47], therefore our data showing that IGF-I induces 
ACCA dephosphorylation suggests that IGF-I sensitises 
ACCA to activation. Additionally, Ser-79 is a critical 
phosphorylation site for ACCA deactivation, therefore the 
effects of IGF-I on ACCA reported here are consistent with 
ACCA activation. Early studies have shown that insulin 
also activates ACCA by reducing its phosphorylation 
[16, 48]. Despite belonging to the insulin family, very few 
studies have demonstrated the effects of IGF-I on ACCA 
phosphorylation. Recently, IGF-I has been shown to 
reduce ACCA phosphorylation in HCT-8 colorectal cancer 
cells, however, IGF-I also reduced the abundance of total 
ACCA, resulting in no net change in ACCA activity or 
lipid synthesis [49].
Our group has previously published that downstream 
of ACCA, IGF-I increases FASN abundance in cells 
expressing full-length, wildtype BRCA1 and that the cells 
are dependent on FASN for their proliferative response 
[23]. The current report presents a novel mechanism 
by which IGF-I induces ACCA dephosphorylation. 
The disruption of the physical association between 
BRCA1 and phosphorylated ACCA has been suggested 
to sensitise ACCA to dephosphorylation [10]. Our 
co-immunoprecipitation studies show that IGF-I 
disrupts this interaction, rendering ACCA susceptible 
to dephosphorylation. While we demonstrate that IGF-I 
reduces the interaction between BRCA1 and p-ACCA 
(S79), we did not investigate the precise mechanism 
in this study. However, available evidence show that 
BRCA1 can also be phosphorylated at multiple sites 
and this phosphorylation is important for its function 
[50], including its interaction with other proteins. Martin 
and Ouchi, 2005 have shown that BRCA1 interacts 
with X-linked inhibitor of apoptosis protein (XIAP) in 
an ovarian carcinoma cell line SNU-251 and that the 
BRCA1-XIAP complex is disrupted by UV-induced 
phosphorylation of BRCA1 [51]. In another study, IGF-I 
induced BRCA1 phosphorylation in an AKT-dependent 
manner in breast and ovarian cancer cell lines [52]. We 
therefore hypothesize that IGF-I may be inducing BRCA1 
phosphorylation in our model, resulting in the dissociation 
of the BRCA1-p-ACCA complex. Our future studies will 
further elucidate this mechanism. 
High circulating levels of IGF-I increase the risk 
of breast cancer in women from families with BRCA 1/2 
mutations [53] and BRCA1 deficiency has been linked to 
an increase in IGF-I in both in vitro and in vivo models 
[22, 30]. In addition to these observational studies, 
investigations of genetic determinants of breast cancer risk 
in BRCA1 mutation carriers have identified associations 
with genetic variants in the IGF-IR [54] and IGF-II 
[55], indicating that the IGF-pathway is causally related 
to breast cancer development in women with BRCA1 
mutations. In this study, we further studied the impact of 
BRCA1 deficiency on the action of excess IGF-I. Our data 
also show that in addition to dissociation of the BRCA1-p-
ACCA (S79) complexes, siRNA-mediated loss of BRCA1 
also renders ACCA susceptible to dephosphorylation. This 
is demonstrated by the enhanced ACCA dephosphorylation 
by IGF-I when BRCA1 was silenced. All the observed 
alterations in lipogenic enzymes are consistent with 
increased de novo fatty acid synthesis, which is supportive 
to cell growth. Proliferating cells are dependent on fatty 
acids for energy and synthesis of biological membranes 
[56, 57]. Consistent with this notion, breast cancer cells 
have been shown to synthesise up to 95% of their fatty 
acids regardless of exogenous supply and this is facilitated 
by upregulation of activity and abundance of fatty acid 
enzymes including ACCA and FASN [58]. 
BRCA1 knockdown also enhanced the effects 
of exogenous IGF-I on AKT as expected, but to our 
surprise, the phosphorylation of the IGF-IRß upstream 
of AKT was slightly reduced. The observed reduction 
in IGF-IRß phosphorylation in response to IGF-I may 
be due to ligand-induced receptor internalisation which 
has been shown to sustain AKT phosphorylation [59]. 
The internalised IGF-I receptors can be recycled to the 
membrane and this process is more energy-efficient 
than de novo receptor synthesis [59]. However, BRCA1 
deficiency may impair receptor recycling in our model, 
which may then be over-compensated for by synthesis of 
new receptor molecules. In spite of this, a longer time-
point may be necessary to observe a high steady-state 
receptor turnover in response to IGF-I. Further studies are 
required to understand the effects of BRCA1 deficiency on 
IGF-I receptor recycling. 
Our group has previously shown that the induction 
of a negative regulator of the IGF-IR/AKT pathway: 
PTEN, desensitises cells to high doses of IGF-II, but 
IGFBP-2, when independent from IGF-II can restore 
the response to high doses by suppressing PTEN [60]. 
In this study, our data show that BRCA1 deficiency 
increases the cellular proliferative response to IGF-I 
and that cells remain sensitised to IGF-I at high doses. 
These observed effects may be mediated through the 
mechanism demonstrated for IGF-II in the Perks et al. 
study. Additionally, we have previously shown that loss 
of PTEN is associated with IGFBP-2 expression [61]. 
Remarkably, we also observed that BRCA1 deficiency in 
this study upregulated IGFBP-2 and PTEN was supressed 
(data not shown). Taken together, these data suggest that 
BRCA1 restrains IGF-I-induced cell proliferation but 
when this restraint is lost due to BRCA1 deficiency, cells 
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proliferate unrestrained partly due to the loss of PTEN and 
upregulated de novo fatty acid synthesis. 
CONCLUSIONS
We report that BRCA1 restrains IGF-I induced cell 
proliferation and that this function is dependent on the 
physical association between BRCA1 and phosphorylated 
ACCA in the cytoplasm of ER-positive breast cancer 
cells. Any cellular event that reduces or abolishes this 
interaction such as IGF-I action or BRCA1 deficiency, 
upregulates fatty acid synthesis and supports cell growth. 
The model presented here suggests an opportunity to target 
the lipogenic pathway in BRCA1-related breast cancers.
MATERIALS AND METHODS
Reagents
Recombinant, human IGF-I peptide was purchased 
from Gropep (Adelaide, South Australia, Australia). 
Okadaic acid was purchased from Calbiochem (San 
Diego, CA, USA).
Cell culture
Human breast cancer cells, MCF-7, T47D, MDA-
MB 231 and Hs578T were purchased from the European 
Collection of Authenticated Cell Cultures (ECACC) and 
maintained as previously published [23]. UBR60-bcl2 
cell line was a generous gift from Professor Paul Harkin 
(Queen’s University of Belfast, Ireland). The UBR60-
bcl2 cell line expresses BRCA1 under the control of 
tetracycline-regulated promoter and has previously been 
described elsewhere [25]. 
siRNA and transfections
Small interfering RNA (siRNA) targeting BRCA1 
were acquired from Qiagen (Manchester, UK) and the 
sequences are as follows; siRNA1 (Hs_siRNA_9): 
5′AACCTATCGGAAGAAGGCAAG-3′ and siRNA2 (Hs-
siRNA_14): 5′-CAGGAAATGGCTGAACTAGAA-3′. All 
stars negative control siRNA (Qiagen, Manchester, UK) 
with no target in the human genome was used as control. 
Transient transfection of siRNA was performed using 
Saint-Red Transfection Reagent (Synvolux Therapeutics, 
Groningen, Netherlands) according to the manufacturer’s 
instructions. Western blotting was used to validate 
knockdown efficiency.
Western blotting
Cells were either lysed directly on culture plates 
and scraped or trypsinised first before lysis using cell 
lysis buffer described elsewhere [62]. Equal amount of 
proteins from lysates were separated on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) 
and transfered onto supported nitrocellulose membranes 
(BioRad, Hertfordshire, UK). Non-specific binding were 
eliminated by incubating membranes with 1% w/v milk 
in tris- buffered saline Tween-20 (TBST) overnight. 
Membranes were then probed with the following 
antibodies according to the manufacturer’s recommended 
dilutions; ACCA (Cell Signaling, Danvers, MA, USA), 
p-ACCA (S79) (Cell Signaling, Danvers, MA, USA), 
FASN (BD Biosciences, Franklin Lakes, NJ, USA), IGF-
IR (Cell Signaling, MA, USA), p-IGF-IR (Y1135/1136) (Cell 
Signaling, Danvers, MA, USA), AKT (Cell Signaling, 
Danvers, MA, USA) and p-AKT (S473) (Cell Signaling, 
Danvers, MA, USA). Membranes were washed and 
incubated with anti-mouse IgG HRP or anti-rabbit IgG 
HRP secondary antibodies. Membranes were washed 
and the signals were detected using SuperSignal West 
Dura and Femto Chemiluminescent Substrates (Thermo 
Scientific, Rockford, IL, USA). The bands were analysed 
using Image J (National Institutes of Health, Bethesda, 
Maryland, USA). 
Tritiated thymidine incorporation assay
Cells were seeded in 24-well plates at 0.025 × 106 
cells per well in growth media and maintained for 24 hrs 
in 5% CO2 at 37° C. Cells were then serum-starved for 
24 hours before dosing with 0, 10, 25, 50, 100 and 200 ng/ml 
IGF-I in serum-free medium for 24 hours. Each IGF-I 
dose was performed in triplicate. In the last 4 hours of 
the experiment, cells were incubated with 0.1 µCi [3H]-
Thymidine (Perkin Elmer, Boston, MA) per well. After 
4 hours, cells were washed with 5% w/v Trichoroacetic 
acid (TCA) (Sigma-Aldrich, St Louis, MO, USA) 
solution for 10 minutes at 4° C. TCA was then removed 
and cells were treated with 1M NaOH (Fisher Scientific 
Ltd, Leicestershire, UK) for 1 hour at room temperature. 
Scintillation fluid (Perkin Elmer, Boston, MA) was added 
and radioactivity was measured in a Liquid Scintillation 
Analyzer (Perkin Elmer, Boston, MA). Data was recorded 
as disintegration per minute (DPM).
Co-immunoprecipitation
Cells were lysed in cell lysis buffer supplemented 
with protease inhibitors and phosphatase inhibitor cocktail 
(Sigma-Aldrich, St Louis, MO, USA). Equal amounts of 
protein (1 mg) from the resulting lysates were incubated 
with 2 µg of anti-BRCA1 (Merck Millipore, Billerica, 
MA, USA), anti-p-ACCA (S79) (Cell Signaling, Danvers, 
MA, USA) and negative control IgG (Dako, Glostrup, 
Denmark) antibodies overnight at 4° C. Lysates were 
then incubated with 10 ug affinity purified secondary 
antibody (Merk-Millipore, Billerica, MA, USA) for 
1 hour, followed by incubation with Protein A/G PLUS 
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immunoprecipitation reagent (Santa Cruz, Dallas, Texas, 
USA) for 1 hour at 4° C. After centrifugation and washing 
with lysis buffer, immune complexes were eluted by 
heating with sample loading buffer (Sigma-Aldrich, St 
Louis, MO, USA) for 5 minutes at 95° C and analysed by 
western blotting.
Subcellular fractionation
Extraction of cytoplasmic and nuclear protein 
fractions was achieved using a NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Thermo Scientific, 
Rockford, IL USA). Whole cell fractions were obtained 
by routine whole cell lysis using cell lysis buffer. Protein 
concentrations were determined using Pierce BCA Protein 
Assay (Thermo Scientific, Rockford, IL USA) and equal 
amounts of cytosolic, nuclear and whole cell extracts were 
analysed by western blotting.
 Immunofluorescence
Cells cultured on 22 × 22 mm coverslips were 
fixed with 4% paraformaldehyde for 20 minutes. Fixed 
cells were permeabilized using 0.5% Triton-X for 
15 minutes and non-specific binding was blocked with 
3% BSA in PBS for 1 hour. For immunostaining, cells 
were incubated with BRCA1 antibody (1:500) for 1 hour 
at room temperature. After washing three times with 
PBS, cells were incubated with secondary antibody for 
1 hour at room temperature. After washing three times 
with PBS, slides were mounted and counterstained 
using Vectashield® Mounting Medium with DAPI (Vecta 
laboratories, H-1200). Slides were then visualised on 
a Zeiss Axio Vert A1 inverted microscope and images 
were captured with a QIClick CCD Camera (Q Imaging) 
interfaced with Q-capture Pro software.
Statistical analyses
Data were analysed using IBM SPSS statistics 
23 (IBM Corporation, version 23.0.0.2) and presented 
as mean ± S.E.M of a minimum of three independent 
experiments. Independent samples t-test was used to 
compare means of two groups and for the means of more 
than two groups, one-way analysis of variance (ANOVA) 
was used followed by a Bonferroni Multiple Comparison 
Test. For both tests, a p-value of equal or less than 0.05 
was considered statistically significant. 
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